Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Glaxosmithkline Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹2,925.50
High
₹2,972.80
Price Summary
| Previous Close | ₹2,958.10 |
|---|---|
| Day's Range | ₹2,925.50 - ₹2,972.80 |
| Open | ₹2,938.90 |
| 52 Week Range | ₹2,088.10 - ₹3,120.70 |
| Volume | 48,109 |
| Market Cap | ₹0.05 |
| Previous Close | ₹2,958.60 |
|---|---|
| Day's Range | ₹2,930.00 - ₹2,965.55 |
| Open | ₹2,965.55 |
| 52 Week Range | ₹2,088.00 - ₹3,121.10 |
| Volume | 1,734 |
| Market Cap | ₹0.05 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,419.80 |
|---|---|
| Market Cap (₹ in Mn) | 0.05 |
| Dividend Yield(%) | 1.93 |
| Price/Earning (TTM) | 46.92 |
| TTM EPS (₹) | 63.05 |
| P/E Ratio | 37.34 |
| Book Value(₹) | 19.89 |
| PAT Margin (%) | 24.54 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 66.79 |
| Trade Value ( ₹ in Lacs) | 51.08 |
|---|---|
| Market Cap (₹ in Mn) | 0.05 |
| Dividend Yield(%) | 1.93 |
| Price/Earning (TTM) | 46.92 |
| TTM EPS (₹) | 63.05 |
| P/E Ratio | 37.34 |
| Book Value(₹) | 19.89 |
| PAT Margin (%) | 24.54 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 66.79 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 8048.3 | 37492.1 |
| Expenses | N/A | N/A |
| PBT | 2785.7 | 12598.8 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 2047.0 | 9275.8 |
About Glaxosmithkline Pharmaceuticals Ltd.
| Founded | 1924 |
|---|---|
| Managing Director | Bhushan Akshikar |
| NSE Symbol | GLAXO |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,55,633.71 | 1,899.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,41,576.41 | 9,100.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,84,478.41 | 4,850.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,24,661.30 | 8,670.00 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,18,977.24 | 684.05 | 0.00 - 0.00 |
| Cipla Ltd. | 1,11,888.39 | 1,385.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,11,820.18 | 1,121.00 | 835.50 - 835.50 |
| Laurus Labs Ltd. | 99,417.45 | 1,840.00 | 823.10 - 823.10 |
| Lupin Ltd. | 96,528.82 | 2,111.00 | 1,900.00 - 1,900.00 |
| Dr. Reddy's Laboratories Ltd. | 96,322.06 | 1,154.00 | 1,101.00 - 1,101.00 |
No Records Found
Latest News
GlaxoSmithKline Pharmaceuticals informs about press release
GlaxoSmithKline Pharmaceuticals informs about board meeting
Pursuant to Regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of our Company will be held on Monday, 3rd August 2026, to consider, approve and take on record the Un-audited financial results for the first quarter ended 30th June 2026.
The above information is a part of company’s filings submitted to BSE.
GlaxoSmithKline Pharmaceuticals informs about disclosure
GlaxoSmithKline Pharmaceuticals informs about letter for weblink for annual report
Aster DM Quality Care submits integrated annual report and AGM notice
In compliance with Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aster DM Quality Care has informed that it enclosed the Integrated Annual Report of the company for the Financial Year 2025-26 along with Notice of the 18th Annual General Meeting (‘AGM’) being held on Monday, 28 September 2026, at 11.30 AM (IST) through Video Conferencing (‘VC’) facility / Other Audio Visual Means (‘OAVM’), to transact the businesses as set forth in the Notice of AGM. The Integrated Annual Report along with the AGM notice are being emailed to the Shareholders of the Company on 4 September 2026, to those Members whose email IDs are registered with the Company/Depository Participant(s) as on Friday, 28 August 2026. Further the company has informed that it has fixed Monday, 21 September 2026, as the cut-off date to reckon the eligibility to vote on the e-voting platform. Further, in accordance with Regulation 36(1)(b) of the Listing Regulations, the Company has dispatched letters to Shareholders whose e-mail addresses are not registered with Company/DPs providing the weblink to access the Integrated Annual Report for FY 2025-26. This intimation is also being uploaded on Company’s website at www.asterqualitycare.com.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Glaxosmithkline Pharmaceuticals Ltd. is ₹2,958.10 as of 2026-09-04.
The market capitalisation of Glaxosmithkline Pharmaceuticals Ltd. is ₹50,120.47 as of 2026-09-04.
The 1-year return of Glaxosmithkline Pharmaceuticals Ltd. is 106.30% as of 2026-09-04.
The P/E ratio of Glaxosmithkline Pharmaceuticals Ltd. is 37.34 as of 2026-09-05.
The 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd. are ₹3,120.70 and ₹2,088.10, respectively, as of 2026-09-04.
People Also Ask
GlaxoSmithKline Pharmaceuticals Ltd. forms partnerships by collaborating with medical professionals and government health agencies to promote mass immunisation and disease awareness. The company ensures a robust supply chain to deliver life-saving medicines consistently to hospitals and regional clinics.
GlaxoSmithKline Pharmaceuticals Ltd. offers an important range of prescription medicines and preventative vaccines. The company focuses heavily on anti-infectives, dermatology, pediatric vaccines, and general medicines, supplying highly trusted pharmaceutical brands to the Indian healthcare system.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
